P70/38/86 (81-45) Approved for use strough 07/31/2012 OA65 0551-0031

Under the Paperwork Peduction Act of 1985, as presents are three	U.S. Parent and Trad meditorespond to a collection of inform	emark Office; U.S. DEPARTMENT OF COMMERCE abon unless it ownsern a valid CMB roome number.
Request	Application Number	10/721,117
for Continued Examination (RCE) Transmittal Address to Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Filing Date	November 25, 2003
	First Named Inventor	Dominic Bennett, et al.
	Art Unit	3688 Cont. No.: 6145
	Examiner Name	Raquel Alvarez
	Attorney Docket Number	CLAR 1067-1 (20GF-143727)
This is a Request for Continued Examination (RCE) under 37 CPR 1.114 of the above-identified application. Recrust for Continued Examination (RCE) practice under 37 CPR 1.114 does not apply to any tality or plant application filed point to lune 8. 1956, or to any does an application. See tradiction Sheef for RCEs forto to be submitted to the 1997(10) an page 2. Submission required under 37 CPR 1.114 Note: If the RCE is proper, any proviously filed unentered amendments and		
amoniferents entoyed with the ROE will be entered in the order in which they were find unless applicant instructs otherwise if applicant does not wish to have any previously filed unsuriesed aroundment(s) entered, applicant must request non-entry of such attendiment(s).		
a Previously indenied. If a final Office action is ourstanding, any amendments filed after the final Office action may be oppositived as a submission even if this box is not checked.		
Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
11 (Alay		
D C Enclosed		
Amendment/Rapty (19 pgs.) iii 🔲 Information Disclosure Statement (ICS)		
ii Afikiavi(s)/ Declaration(s)	iv. 🛭 Other Po	ntition for Extension of Time (2 pgs.)
2 Miscellaneous		
Suspension of action on the above-identified application is requested under 37 CFR 1.193(c) for a		
pelica of		
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is find. The Director is nevely authorized to charge the following less, any underpayment of facts, or credit any overpayments, to		
a 💢 Deposit Account No. 50-4551		
CE fine required under 37 CFR 1 17(e)		
#		
5 Check in the amount of \$		
c Payment by credit card (Fore PTO-Rtol encirsed)		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
	NT, ATTORNEY, OR AGENT RE	
Signature Name (Print/Type) Daniel C./GKS	Date	August 25, 2009 stration No. 58.417
Name (Print/Typis) Daniel C., (NSKa Registration No. 68,417 CERTIFICATE OF MAILING OR TRANSMISSION		
I hereby centry that the correspondence is being filed electronically via EFS-Web addressed to the Commissioner for Patiens on the date		
snown poken. Signatura Letalde R. Robert		
Neme (Print/Type) Linda K Brost	Date	August 25, 2009
The code/door of internation is required by 27 CFR 1.118. The reformation is required to obtain or return a benefit by the process which is to the good by the URFTO to process on application. Confidentially is governed by 35 13 CF. 122 and 27 CFR 1.11 and 1 to The related on a calculated by any 12 remarks or companies, including a place included gaps for confident application place. Any confidence of the related of the results of the related of the rel		

The strain of the properties of control of the first strain of the properties of the

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacehold form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2): (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process audior examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine-your submission, which may result in termination of proceedings or abandonment of the application or expossion of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Phrazy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative thourst, including disclosures to consolir counsel in the course of settlement hesolations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pentains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 LLS C. 5524(m).
- 5. A record related to an international Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Promerty Organization, suggisted to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purpose of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a nouther use, to the Administrator. General Services, or hisher designed, cluning an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906 Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) to issuance of a patent pursuant to 35 U.S.C. 127(b) to issuance of a patent pursuant to 35 U.S.C. 127(b) to issuance of a patent pursuant to 35 U.S.C. 127(b) to its patent pursuant to 35 U.S.C. 127(b) to its patent pursuant to 35 U.S.C. 127(b) to its patent became abondoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routins use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.